

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI174465

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Intergalactic Therapeutics, Inc.	03/18/2024
RECEIVING PARTY DATA	
Company Name:	Aldevron, LLC
Street Address:	4055 41st Avenue South
City:	Fargo
State/Country:	NORTH DAKOTA
Postal Code:	58104
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	11324839
Patent Number:	11766490
Patent Number:	11602569
Patent Number:	11684680
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6173417533
Email:	phpatentcorrespondence@morganlewis.com,amanda.mcintyre@morganlewis.com
Correspondent Name:	Morgan, Lewis & Bockius LLP
Address Line 1:	2222 MARKET STREET
Address Line 4:	Philadelphia, PENNSYLVANIA 19103
ATTORNEY DOCKET NUMBER:	IGT-003xx/138289-5003
NAME OF SUBMITTER:	Amanda McIntyre
SIGNATURE:	Amanda McIntyre
DATE SIGNED:	04/18/2024
Total Attachments: 9	
source=Intergalactic_IP Assignment_AgreementIGTxsig#page1.tif	
source=Intergalactic_IP Assignment_AgreementIGTxsig#page2.tif	
source=Intergalactic_IP Assignment_AgreementIGTxsig#page3.tif	

source=Intergalactic_IP Assignment_AgreementlGTxsig#page4.tif
source=Intergalactic_IP Assignment_AgreementlGTxsig#page5.tif
source=Intergalactic_IP Assignment_AgreementlGTxsig#page6.tif
source=Intergalactic_IP Assignment_AgreementlGTxsig#page7.tif
source=Intergalactic_IP Assignment_AgreementlGTxsig#page8.tif
source=Intergalactic_IP Assignment_AgreementlGTxsig#page9.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this “Assignment”), effective as of March __, 2024 (the “Effective Date”), is by and between Aldevron, LLC, a North Dakota limited liability company (“Assignee”) and Intergalactic Therapeutics, Inc., a Delaware corporation (“Assignor”).

WITNESSETH:

WHEREAS, pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, dated March 1, 2024, as amended (the “Asset Purchase Agreement”), between Assignee and Assignor, Assignor has agreed to sell to Assignee, and Assignee has agreed to purchase from Assignor, among other things, the Purchased Assets; and

WHEREAS, pursuant to the Asset Purchase Agreement, Assignor desires to sell, assign, convey, deliver and transfer the entire right, title and interest in, to and under all of the Intellectual Property included in the Purchased Assets, including the Intellectual Property as set forth on Exhibit A hereto (the “Assigned IP”), to Assignee and Assignee desires to acquire the entire right, title and interest in, to and under such Assigned IP.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Asset Purchase Agreement and subject to the terms and conditions therein as approved by the Sale Order, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to such terms in the Asset Purchase Agreement.
2. Assignor hereby irrevocably sells, assigns, conveys, delivers and transfers to Assignee the entire right, title and interest in, to and under (i) the Assigned IP, together with all goodwill associated therewith, in each case to be held and enjoyed by Assignee for its own use and enjoyment as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made, including the right to claim priority under the International Convention for the Protection of Industrial Property and under any other international arrangement to which the United States of America is or hereafter becomes a signatory (but not, for the avoidance of doubt, any Excluded Liability), (ii) all rights to sue, claim and recover for past, present and future infringement, misappropriation, dilution or other violation of any Assigned IP, and (iii) all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing.
3. Concurrent with the execution of this Assignment, Assignor shall transfer any and all domain names and social media accounts included in the Assigned IP from Assignor’s account to Assignee’s account (such that Assignee will be listed as the registrant and/or owner of such domain names and social media accounts in the applicable registrar) and shall deliver to Assignee all necessary Auth-Info codes and all other required passwords necessary to unlock and control such domain names and social media accounts.

4. Upon the reasonable request by Assignee, Assignor shall execute all documents and take all actions as may be necessary or desirable to enable Assignee to prosecute, perfect, enforce, defend, register and/or record its right, title and interest in, to and under the Assigned IP, in each case, without further compensation but at the expense of Assignee. In the event that Assignor fails to execute any such document or take any such action as set forth in the preceding sentence, Assignor hereby designates Assignee as Assignor's agent, and hereby grants to Assignee a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of executing such documents or taking such actions.

5. Assignor hereby authorizes and requests the officials of the United States Copyright Office and the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign jurisdiction, to record and register Assignee as assignee and owner of the entire right, title and interest in, to and under the Assigned IP.

6. Section 10.12 of the Purchase Agreement is hereby incorporated by reference into this Agreement and shall apply as if fully set forth herein *mutatis mutandis*.

7. This Assignment is binding upon, and inures to the benefit of, the parties hereto and their respective legal representatives, successors and assigns. No waiver, modification or change of any provision of this Assignment shall be valid unless in writing and signed by the party against whom such claimed waiver, modification or change is sought to be enforced.

8. This Assignment may be executed in counterparts in electronic form or by hand, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto, through their authorized representatives, have caused this Assignment to be duly executed and delivered as of the Effective Date.

AS ASSIGNOR:

INTERGALACTIC THERAPEUTICS, INC.

By: Charles Allen

Name: Charles Allen

Title: President

STATE OF Massachusetts
COUNTY OF Middlesex) ss

On the 18th day of March, 2024, before me personally came Charles Allen, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as President of Intergalactic Therapeutics, Inc., the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

Robert E. Richards, Jr.

Notary Public



(PLACE STAMP AND SEAL ABOVE)

[Signature Page to Intellectual Property Assignment Agreement]

IN WITNESS WHEREOF, the parties hereto, through their authorized representatives, have caused this Assignment to be duly executed and delivered as of the Effective Date.

AS ASSIGNEE:

ALDEVRON, LLC

By: _____


Name: Jennifer Meade

Title: President

STATE OF North Dakota
COUNTY OF Cass) ss

On the 18th day of March 2024, before me personally came Jennifer Meade, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as of March 18, 2024, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

Tanya L. Abraham
Notary Public



(PLACE STAMP AND SEAL ABOVE)

[Signature Page to Intellectual Property Assignment Agreement]

INTERGALACTIC THERAPEUTICS PATENT SCHEDULE (March 14, 2024)
CONFIDENTIAL

Family No. MLB Reference	Family Title	Title / Family Description	Country	Application No. (Filing Date)	Patent No.	Status (Action)
1 5002 (IGT-002)	Synthetic C ³ DNA 1	SYNTHETIC DNA VECTORS AND METHODS OF USE Directed to synthetic closed covalent circular DNA (C ³ DNA), methods of producing synthetic C ³ DNA, and methods of using C ³ DNA for treatment of diseases. Includes disclosures directed to C ³ DNA encoding ABCA4 and other ocular genes for treatment of retinal dystrophies, such as Stargardt disease.	U.S. Provisional	62/643,336 (3/15/2018)		Expired provisional
			U.S. Provisional	62/749,369 (10/23/2018)		Expired provisional
			PCT/International	PCT/US19/22511 (3/15/2019)		Published / closed
			U.S.	16/980,914 (9/15/2020)		Pending
			Australia	201923390 (3/15/2019)		Pending
			Canada	3092088 (3/15/2019)		Pending
			China	201980049118.X (3/15/2019)		Abandoned
			China (Div)	202311181118.4 (3/15/2019)		Pending
			Europe	19766752.0 (3/15/2019)		Pending
			Hong Kong (from EP)	62021033338.6 (6/18/2021)		Pending
			Israel	276923 (3/15/2019)		Pending
			India	202017037925 (3/15/2019)		Pending
			Japan	2020545324 (3/15/2019)		Abandoned
2 5003 (IGT-003)	Synthetic C ³ DNA 2	SYNTHETIC DNA VECTORS AND METHODS OF USE Includes and expands the subject matter of Family 1 (synthetic C ³ DNA) to include other disease indications, such as oncology. Claims broadly issued in US for synthetic C ³ DNA lacking an origin of replication, drug resistance gene, and recombination site.	Japan (Div)	2023-222352 (3/15/2019)		Pending
			Korea	1020207028218 (3/15/2019)		Pending
			Mexico	MX/a/2020/00579 (3/15/2019)		Pending
			U.S. Provisional	62/902,084 (9/18/2019)		Expired provisional
			PCT/International	PCT/US20/51507 (9/18/2020)		Published / closed
			U.S.	17/365,805 (7/11/2021)		Abandoned
			U.S.	17/365,808 (7/11/2021)	11,324,839	Granted
			U.S.	17/365,846 (7/11/2021)	11,766,490	Granted
			U.S.	17/675,899 (2/18/2022)	11,602,569	Granted
			U.S.	18/057,032 (11/18/2022)	11,684,680	Granted

DBI/ 141288199.3

INTERGALACTIC THERAPEUTICS PATENT SCHEDULE (March 14, 2024)
CONFIDENTIAL

Family No. MLB Reference	Family Title	Title / Family Description	Country	Application No. (Filing Date)	Patent No.	Status (Action)
			U.S.	18/308,457 (4/27/2023)		Pending
			Europe	20866548.9 (9/18/2020)		Pending
			United Kingdom	2204355.8 (9/18/2020)		Pending
			Australia	2020351204 (9/18/2020)		Pending
			Canada	3151464 (9/18/2020)		Pending
			China	202080080113.9 (9/18/2020)		Pending
			Taiwan	109132490 (9/18/2020)		Pending
			Israel	291437 (9/18/2020)		Pending
			India	202217022159 (9/18/2020)		Pending
			Japan	2022-517337 (9/18/2020)		Pending
		SYNTHETIC PRODUCTION OF CIRCULAR DNA VECTORS	Korea	10-2022-7012373 (9/18/2020)		Pending
			Mexico	MX/a/2022/003291 (9/18/2020)		Pending
			U.S. Provisional	63/248,801 (9/27/2021)		Expired provisional
			PCT/International	PCT/US22/77108 (9/27/22)		Published
3	Cell-free production of C ³ DNA	Directed to methods of producing synthetic C ³ DNA in a cell-free system using restriction endonuclease digestion.				
4	Bacterially produced C ³ DNA	BACTERIALLY PRODUCED C ³ DNA	U.S. Provisional	63/291,871 (12/23/21)		Expired provisional
			PCT/International	PCT/US22/82078 (12/23/21)		Published
5	Peptides for gene delivery	POLYPEPTIDES AND METHODS OF USE	Provisional / U.S.	63/331,452 (4/19/2022)		Expired provisional
5013 (IGT-013)		Directed to peptides and nanoparticles that can improve cellular uptake of non-viral vectors, such as C ³ DNA.	PCT/ International	PCT/US2023/065763 (4/14/2023)		Published
6	Ocular electrotransfer	OCULAR DELIVERY OF THERAPEUTIC AGENTS	U.S. Provisional	63/163,350 (3/19/2021)		Expired provisional
5010 (IGT-010)			U.S. Provisional	63/167,296		Expired provisional

INTERGALACTIC THERAPEUTICS PATENT SCHEDULE (March 14, 2024)
CONFIDENTIAL

Family No. MLB Reference	Family Title	Title / Family Description	Country	Application No. (Filing Date)	Patent No.	Status (Action)
		Directed to methods of delivering non-viral vectors to the eye using electrotransfer. Specific embodiments include delivery of C ³ DNA encoding genes such as ABCA4 to the retina for treatment of retinal dystrophies, such as Stargardt disease. Also included are electrodes desired for ocular electrotransfer.	U.S. Provisional	(3/29/21) 63/167,463 (3/29/21)		Expired provisional
			U.S. Provisional	63/167,437 (3/29/2021) 63/293,297 (12/23/21)		Expired provisional
			U.S. Provisional	63/316,699 (3/4/22)		Expired provisional
			PCT/International	PCT/US22/21209 (3/21/2022)		Published / closed
			U.S.	17/721,963 (4/14/2022) 18/156,891 (1/19/23)		Abandoned
			U.S.	18/491,140 (10/20/2023) 2022238492 (3/21/2022)		Pending
			Australia	2022238492 (3/21/2022)		Pending
			Canada	3,212,469 (3/21/2022)		Pending
			China	202280035586.8 (3/21/2022)		Pending
			Europe	22772345.9 (3/21/2022)		Pending
7 5012 (IGT-012)	Front-of-the-eye electrotransfer	GENE THERAPIES FOR THE FRONT OF THE EYE Directed to methods of delivering non-viral vectors to the front of the eye using electrotransfer. Specific embodiments include delivery of C ³ DNA to the front of the eye for treatment of Ruchs' dystrophy.	Israel	306009 (3/21/2022)		Pending
			India	202317071092 (3/21/2022)		Pending
			Japan	2023-557754 (3/21/2022)		Pending
			Korea	10-2023-703697 (3/21/2022)		Pending
			Mexico	MX/a/2023/010899 (3/21/2022)		Pending
			U.S. Provisional	63/444,740 (2/10/2023)		Expired provisional
			PCT/International	PCT/US2024/015101 (2/9/2024)		PCT Pending
			U.S. Provisional	63/359,125 (7/7/2022)		Expired provisional
			U.S. Provisional	63/408,353		Expired provisional
			8 5006 (IGT-006) 5007 (IGT-007) 5008 (IGT-008) 5009 (IGT-009) 5010 (IGT-010) 5011 (IGT-011) 5012 (IGT-012) 5013 (IGT-013) 5014 (IGT-014) 5015 (IGT-015) 5016 (IGT-016) 5017 (IGT-017) 5018 (IGT-018) 5019 (IGT-019) 5020 (IGT-020) 5021 (IGT-021) 5022 (IGT-022) 5023 (IGT-023) 5024 (IGT-024) 5025 (IGT-025) 5026 (IGT-026) 5027 (IGT-027) 5028 (IGT-028) 5029 (IGT-029) 5030 (IGT-030) 5031 (IGT-031) 5032 (IGT-032) 5033 (IGT-033) 5034 (IGT-034) 5035 (IGT-035) 5036 (IGT-036) 5037 (IGT-037) 5038 (IGT-038) 5039 (IGT-039) 5040 (IGT-040) 5041 (IGT-041) 5042 (IGT-042) 5043 (IGT-043) 5044 (IGT-044) 5045 (IGT-045) 5046 (IGT-046) 5047 (IGT-047) 5048 (IGT-048) 5049 (IGT-049) 5050 (IGT-050) 5051 (IGT-051) 5052 (IGT-052) 5053 (IGT-053) 5054 (IGT-054) 5055 (IGT-055) 5056 (IGT-056) 5057 (IGT-057) 5058 (IGT-058) 5059 (IGT-059) 5060 (IGT-060) 5061 (IGT-061) 5062 (IGT-062) 5063 (IGT-063) 5064 (IGT-064) 5065 (IGT-065) 5066 (IGT-066) 5067 (IGT-067) 5068 (IGT-068) 5069 (IGT-069) 5070 (IGT-070) 5071 (IGT-071) 5072 (IGT-072) 5073 (IGT-073) 5074 (IGT-074) 5075 (IGT-075) 5076 (IGT-076) 5077 (IGT-077) 5078 (IGT-078) 5079 (IGT-079) 5080 (IGT-080) 5081 (IGT-081) 5082 (IGT-082) 5083 (IGT-083) 5084 (IGT-084) 5085 (IGT-085) 5086 (IGT-086) 5087 (IGT-087) 5088 (IGT-088) 5089 (IGT-089) 5090 (IGT-090) 5091 (IGT-091) 5092 (IGT-092) 5093 (IGT-093) 5094 (IGT-094) 5095 (IGT-095) 5096 (IGT-096) 5097 (IGT-097) 5098 (IGT-098) 5099 (IGT-099) 5100 (IGT-100) 5101 (IGT-101) 5102 (IGT-102) 5103 (IGT-103) 5104 (IGT-104) 5105 (IGT-105) 5106 (IGT-106) 5107 (IGT-107) 5108 (IGT-108) 5109 (IGT-109) 5110 (IGT-110) 5111 (IGT-111) 5112 (IGT-112) 5113 (IGT-113) 5114 (IGT-114) 5115 (IGT-115) 5116 (IGT-116) 5117 (IGT-117) 5118 (IGT-118) 5119 (IGT-119) 5120 (IGT-120) 5121 (IGT-121) 5122 (IGT-122) 5123 (IGT-123) 5124 (IGT-124) 5125 (IGT-125) 5126 (IGT-126) 5127 (IGT-127) 5128 (IGT-128) 5129 (IGT-129) 5130 (IGT-130) 5131 (IGT-131) 5132 (IGT-132) 5133 (IGT-133) 5134 (IGT-134) 5135 (IGT-135) 5136 (IGT-136) 5137 (IGT-137) 5138 (IGT-138) 5139 (IGT-139) 5140 (IGT-140) 5141 (IGT-141) 5142 (IGT-142) 5143 (IGT-143) 5144 (IGT-144) 5145 (IGT-145) 5146 (IGT-146) 5147 (IGT-147) 5148 (IGT-148) 5149 (IGT-149) 5150 (IGT-150) 5151 (IGT-151) 5152 (IGT-152) 5153 (IGT-153) 5154 (IGT-154) 5155 (IGT-155) 5156 (IGT-156) 5157 (IGT-157) 5158 (IGT-158) 5159 (IGT-159) 5160 (IGT-160) 5161 (IGT-161) 5162 (IGT-162) 5163 (IGT-163) 5164 (IGT-164) 5165 (IGT-165) 5166 (IGT-166) 5167 (IGT-167) 5168 (IGT-168) 5169 (IGT-169) 5170 (IGT-170) 5171 (IGT-171) 5172 (IGT-172) 5173 (IGT-173) 5174 (IGT-174) 5175 (IGT-175) 5176 (IGT-176) 5177 (IGT-177) 5178 (IGT-178) 5179 (IGT-179) 5180 (IGT-180) 5181 (IGT-181) 5182 (IGT-182) 5183 (IGT-183) 5184 (IGT-184) 5185 (IGT-185) 5186 (IGT-186) 5187 (IGT-187) 5188 (IGT-188) 5189 (IGT-189) 5190 (IGT-190) 5191 (IGT-191) 5192 (IGT-192) 5193 (IGT-193) 5194 (IGT-194) 5195 (IGT-195) 5196 (IGT-196) 5197 (IGT-197) 5198 (IGT-198) 5199 (IGT-199) 5200 (IGT-200) 5201 (IGT-201) 5202 (IGT-202) 5203 (IGT-203) 5204 (IGT-204) 5205 (IGT-205) 5206 (IGT-206) 5207 (IGT-207) 5208 (IGT-208) 5209 (IGT-209) 5210 (IGT-210) 5211 (IGT-211) 5212 (IGT-212) 5213 (IGT-213) 5214 (IGT-214) 5215 (IGT-215) 5216 (IGT-216) 5217 (IGT-217) 5218 (IGT-218) 5219 (IGT-219) 5220 (IGT-220) 5221 (IGT-221) 5222 (IGT-222) 5223 (IGT-223) 5224 (IGT-224) 5225 (IGT-225) 5226 (IGT-226) 5227 (IGT-227) 5228 (IGT-228) 5229 (IGT-229) 5230 (IGT-230) 5231 (IGT-231) 5232 (IGT-232) 5233 (IGT-233) 5234 (IGT-234) 5235 (IGT-235) 5236 (IGT-236) 5237 (IGT-237) 5238 (IGT-238) 5239 (IGT-239) 5240 (IGT-240) 5241 (IGT-241) 5242 (IGT-242) 5243 (IGT-243) 5244 (IGT-244) 5245 (IGT-245) 5246 (IGT-246) 5247 (IGT-247) 5248 (IGT-248) 5249 (IGT-249) 5250 (IGT-250) 5251 (IGT-251) 5252 (IGT-252) 5253 (IGT-253) 5254 (IGT-254) 5255 (IGT-255) 5256 (IGT-256) 5257 (IGT-257) 5258 (IGT-258) 5259 (IGT-259) 5260 (IGT-260) 5261 (IGT-261) 5262 (IGT-262) 5263 (IGT-263) 5264 (IGT-264) 5265 (IGT-265) 5266 (IGT-266) 5267 (IGT-267) 5268 (IGT-268) 5269 (IGT-269) 5270 (IGT-270) 5271 (IGT-271) 5272 (IGT-272) 5273 (IGT-273) 5274 (IGT-274) 5275 (IGT-275) 5276 (IGT-276) 5277 (IGT-277) 5278 (IGT-278) 5279 (IGT-279) 5280 (IGT-280) 5281 (IGT-281) 5282 (IGT-282) 5283 (IGT-283) 5284 (IGT-284) 5285 (IGT-285) 5286 (IGT-286) 5287 (IGT-287) 5288 (IGT-288) 5289 (IGT-289) 5290 (IGT-290) 5291 (IGT-291) 5292 (IGT-292) 5293 (IGT-293) 5294 (IGT-294) 5295 (IGT-295) 5296 (IGT-296) 5297 (IGT-297) 5298 (IGT-298) 5299 (IGT-299) 5300 (IGT-300) 5301 (IGT-301) 5302 (IGT-302) 5303 (IGT-303) 5304 (IGT-304) 5305 (IGT-305) 5306 (IGT-306) 5307 (IGT-307) 5308 (IGT-308) 5309 (IGT-309) 5310 (IGT-310) 5311 (IGT-311) 5312 (IGT-312) 5313 (IGT-313) 5314 (IGT-314) 5315 (IGT-315) 5316 (IGT-316) 5317 (IGT-317) 5318 (IGT-318) 5319 (IGT-319) 5320 (IGT-320) 5321 (IGT-321) 5322 (IGT-322) 5323 (IGT-323) 5324 (IGT-324) 5325 (IGT-325) 5326 (IGT-326) 5327 (IGT-327) 5328 (IGT-328) 5329 (IGT-329) 5330 (IGT-330) 5331 (IGT-331) 5332 (IGT-332) 5333 (IGT-333) 5334 (IGT-334) 5335 (IGT-335) 5336 (IGT-336) 5337 (IGT-337) 5338 (IGT-338) 5339 (IGT-339) 5340 (IGT-340) 5341 (IGT-341) 5342 (IGT-342) 5343 (IGT-343) 5344 (IGT-344) 5345 (IGT-345) 5346 (IGT-346) 5347 (IGT-347) 5348 (IGT-348) 5349 (IGT-349) 5350 (IGT-350) 5351 (IGT-351) 5352 (IGT-352) 5353 (IGT-353) 5354 (IGT-354) 5355 (IGT-355) 5356 (IGT-356) 5357 (IGT-357) 5358 (IGT-358) 5359 (IGT-359) 5360 (IGT-360) 5361 (IGT-361) 5362 (IGT-362) 5363 (IGT-363) 5364 (IGT-364) 5365 (IGT-365) 5366 (IGT-366) 5367 (IGT-367) 5368 (IGT-368) 5369 (IGT-369) 5370 (IGT-370) 5371 (IGT-371) 5372 (IGT-372) 5373 (IGT-373) 5374 (IGT-374) 5375 (IGT-375) 5376 (IGT-376) 5377 (IGT-377) 5378 (IGT-378) 5379 (IGT-379) 5380 (IGT-380) 5381 (IGT-381) 5382 (IGT-382) 5383 (IGT-383) 5384 (IGT-384) 5385 (IGT-385) 5386 (IGT-386) 5387 (IGT-387) 5388 (IGT-388) 5389 (IGT-389) 5390 (IGT-390) 5391 (IGT-391) 5392 (IGT-392) 5393 (IGT-393) 5394 (IGT-394) 5395 (IGT-395) 5396 (IGT-396) 5397 (IGT-397) 5398 (IGT-398) 5399 (IGT-399) 5400 (IGT-400) 5401 (IGT-401) 5402 (IGT-402) 5403 (IGT-403) 5404 (IGT-404) 5405 (IGT-405) 5406 (IGT-406) 5407 (IGT-407) 5408 (IGT-408) 5409 (IGT-409) 5410 (IGT-410) 5411 (IGT-411) 5412 (IGT-412) 5413 (IGT-413) 5414 (IGT-414) 5415 (IGT-415) 5416 (IGT-416) 5417 (IGT-417) 5418 (IGT-418) 5419 (IGT-419) 5420 (IGT-420) 5421 (IGT-421) 5422 (IGT-422) 5423 (IGT-423) 5424 (IGT-424) 5425 (IGT-425) 5426 (IGT-426) 5427 (IGT-427) 5428 (IGT-428) 5429 (IGT-429) 5430 (IGT-430) 5431 (IGT-431) 5432 (IGT-432) 5433 (IGT-433) 5434 (IGT-434) 5435 (IGT-435) 5436 (IGT-436) 5437 (IGT-437) 5438 (IGT-438) 5439 (IGT-439) 5440 (IGT-440) 5441 (IGT-441) 5442 (IGT-442) 5443 (IGT-443) 5444 (IGT-444) 5445 (IGT-445) 5446 (IGT-446) 5447 (IGT-447) 5448 (IGT-448) 5449 (IGT-449) 5450 (IGT-450) 5451 (IGT-451) 5452 (IGT-452) 5453 (IGT-453) 5454 (IGT-454) 5455 (IGT-455) 5456 (IGT-456) 5457 (IGT-457) 5458 (IGT-458) 5459 (IGT-459) 5460 (IGT-460) 5461 (IGT-461) 5462 (IGT-462) 5463 (IGT-463) 5464 (IGT-464) 5465 (IGT-465) 5466 (IGT-466) 5467 (IGT-467) 5468 (IGT-468) 5469 (IGT-469) 5470 (IGT-470) 5471 (IGT-471) 5472 (IGT-472) 5473 (IGT-473) 5474 (IGT-474) 5475 (IGT-475) 5476 (IGT-476) 5477 (IGT-477) 5478 (IGT-478) 5479 (IGT-479) 5480 (IGT-480) 5481 (IGT-481) 5482 (IGT-482) 5483 (IGT-483) 5484 (IGT-484) 5485 (IGT-485) 5486 (IGT-486) 5487 (IGT-487) 5488 (IGT-488) 5489 (IGT-489) 5490 (IGT-490) 5491 (IGT-491) 5492 (IGT-492) 5493 (IGT-493) 5494 (IGT-494) 5495 (IGT-495) 5496 (IGT-496) 5497 (IGT-497) 5498 (IGT-498) 5499 (IGT-499) 5500 (IGT-500) 5501 (IGT-501) 5502 (IGT-502) 5503 (IGT-503) 5504 (IGT-504) 5505 (IGT-505) 5506 (IGT-506) 5507 (IGT-507) 5508 (IGT-508) 5509 (IGT-509) 5510 (IGT-510) 5511 (IGT-511) 5512 (IGT-512) 5513 (IGT-513) 5514 (IGT-514) 5515 (IGT-515) 5516 (IGT-516) 5517 (IGT-517) 5518 (IGT-518) 5519 (IGT-519) 5520 (IGT-520) 5521 (IGT-521) 5522 (IGT-522) 5523 (IGT-523) 5524 (IGT-524) 5525 (IGT-525) 5526 (IGT-526) 5527 (IGT-527) 5528 (IGT-528) 5529 (IGT-529) 5530 (IGT-530) 5531 (IGT-531) 5532 (IGT-532) 5533 (IGT-533) 5534 (IGT-534) 5535 (IGT-535) 5536 (IGT-536) 5537 (IGT-537) 5538 (IGT-538) 5539 (IGT-539) 5540 (IGT-540) 5541 (IGT-541) 5542 (IGT-542) 5543 (IGT-543) 5544 (IGT-544) 5545 (IGT-545) 5546 (IGT-546) 5547 (IGT-547) 5548 (IGT-548) 5549 (IGT-549) 5550 (IGT-550) 5551 (IGT-551) 5552 (IGT-552) 5553 (IGT-553) 5554 (IGT-554) 5555 (IGT-555) 5556 (IGT-556) 5557 (IGT-557) 5558 (IGT-558) 5559 (IGT-559) 5560 (IGT-560) 5561 (IGT-561) 5562 (IGT-562) 5563 (IGT-563) 5564 (IGT-564) 5565 (IGT-565) 5566 (IGT-566) 5567 (IGT-567) 5568 (IGT-568) 5569 (IGT-569) 5570 (IGT-570) 5571 (IGT-571) 5572 (IGT-572) 5573 (IGT-573) 5574 (IGT-574) 5575 (IGT-575) 5576 (IGT-576) 5577 (IGT-577) 5578 (IGT-578) 5579 (IGT-579) 5580 (IGT-580) 5581 (IGT-581) 5582 (IGT-582) 5583 (IGT-583) 5584 (IGT-584) 5585 (IGT-585) 5586 (IGT-586) 5587 (IGT-587) 5588 (IGT-588) 5589 (IGT-589) 5590 (IGT-590) 5591 (IGT-591) 5592 (IGT-592) 5593 (IGT-593) 5594 (IGT-594) 5595 (IGT-595) 5596 (IGT-596) 5597 (IGT-597) 5598 (IGT-598) 5599 (IGT-599) 5600 (IGT-600) 5601 (IGT-601) 5602 (IGT-602) 5603 (IGT-603) 5604 (IGT-604) 5605 (IGT-605) 5606 (IGT-606) 5607 (IGT-607) 5608 (IGT-608) 5609 (IGT-609) 5610 (IGT-610) 5611 (IGT-611) 5612 (IGT-612) 5613 (IGT-613) 5614 (IGT-614) 5615 (IGT-615) 5616 (IGT-616) 5617 (IGT-617) 5618 (IGT-618) 5619 (IGT-619) 5620 (IGT-620) 5621 (IGT-621) 5622 (IGT-622) 5623 (IGT-623) 5624 (IGT-624) 5625 (IGT-625) 5626 (IGT-626) 5627 (IGT-627) 5628 (IGT-628) 5629 (IGT-629) 5630 (IGT-630) 5631 (IGT-631) 5632 (IGT-632) 5633 (IGT-633) 5634 (IGT-634) 5635 (IGT-635) 5636 (IGT-636) 5637 (IGT-637) 5638 (IGT-638) 5639 (IGT-639) 5640 (IGT-640) 5641 (IGT-641) 5642 (IGT-642) 5643 (IGT-643) 5644 (IGT-644) 5645 (IGT-645) 5646 (IGT-646) 5647 (IGT-647) 5648 (IGT-648) 5649 (IGT-649) 5650 (IGT-650) 5651 (IGT-651) 5652 (IGT-			

INTERGALACTIC THERAPEUTICS PATENT SCHEDULE (March 14, 2024)
CONFIDENTIAL

Family No. MILB Reference	Family Title	Title / Family Description	Country	Application No. (Filing Date)	Patent No.	Status (Action)
9 5007 (IGT-007)	Respiratory C ³ DNA and electrotransfer	RESPIRATORY DELIVERY OF THERAPEUTIC AGENTS				
				Directed to vector compositions containing regulatory sequences that improve expression in retinal cells.		
				PCT/International (9/20/22)	PCT/US23/69748 (7/7/2023)	PCT Pending
				U.S. Provisional (BEST1) (9/20/2022)	63/408,356 (9/20/2022)	Expired provisional
				PCT/International (BEST1) (9/18/2023)	PCT/US23/74441 (9/18/2023)	PCT Pending
10 5011 (IGT-011)	Devices for respiratory electrotransfer	DIRECTED TO METHODS OF DELIVERING NON-VIRAL VECTORS TO AIRWAY TISSUE CELLS USING ELECTROTRANSFER.				
				Directed to methods of delivering non-viral vectors to airway tissue cells using electrotransfer.		
				U.S. Provisional (10/15/2021)	63/256,416 (10/15/2021)	Expired provisional
11 5008 (IGT-008)	Respiratory DNA constructs	DEVICES AND METHODS FOR HOLLOW TISSUE ELECTROTRANSFER				
				Directed to electrode devices for electrotransfer of non-viral vectors to hollow tissues, such as airway.		
				U.S. Provisional (7/13/2022)	63/388,794 (7/13/2022)	Expired provisional
12 5009 (IGT-009)	Oncology vectors and electrotransfer	RESPIRATORY DNA CONSTRUCTS				
				Directed to vector compositions containing regulatory sequences that improve expression in airway cells.		
				U.S. Provisional (7/13/2023)	63/388,880 (7/13/2023)	Expired provisional
13 5014 (IGT-014)	bacc3DNA Family 2 provisional	NUCLEIC ACID VECTORS AND METHODS OF USE				
				Directed to vector compositions encoding anti-cancer agents.		
				PCT/International (2/23/2022)	PCT/US22/70108 (2/23/2022)	PCT pending
				U.S. Provisional (2/23/2021)	63/152,575 (2/23/2021)	Expired provisional
				U.S. Provisional (2/23/2021)	63/152,540 (2/23/2021)	Expired provisional
				PCT/International (2/23/2022)	PCT/US22/7575 (2/23/2022)	Published / closed
				China (2/23/2022)	2022800303312 (2/23/2022)	Pending
				Europe (2/23/2022)	22760356.0 (2/23/2022)	Pending
				Japan (2/23/2022)	2023-551099 (2/23/2022)	Pending
				U.S. (8/22/2023)	18/278,235 (8/22/2023)	Pending
13 5014 (IGT-014)	bacc3DNA Family 2 provisional	GENE THERAPY VECTORS AND METHODS OF PRODUCTION AND USE THEREOF				
				Developments for bacterially-produced C ³ DNA including minimal origin of replication and		
13 5014 (IGT-014)	bacc3DNA Family 2 provisional	GENE THERAPY VECTORS AND METHODS OF PRODUCTION AND USE THEREOF				
				U.S. provisional (6/21/2023)	63/509,458 (6/21/2023)	Pending

INTERGALACTIC THERAPEUTICS PATENT SCHEDULE (March 14, 2024)
CONFIDENTIAL

Family No. MLB Reference	Family Title	Title / Family Description	Country	Application No. (Filing Date)	Patent No.	Status (Action)
		methods for production including using transposase.				

CONFIDENTIAL